Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
debio 1562 + rituximab
- Development stage
- Unknown
- Lead developer
- Debiopharm
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Debio 1562 + rituximab is an investigational combination therapy evaluated for patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin’s lymphoma subtypes. **Debio 1562** is a first-in-class antibody-drug conjugate (ADC) targeting CD37, consisting of an anti-CD37 monoclonal antibody (naratuximab), a proprietary MultiLink™ linker, and a microtubule inhibitor payload. It is designed for selective delivery to CD37-expressing malignant B cells, disrupting their survival by cytotoxic tubulin inhibition. **Rituximab** is a monoclonal antibody targeting CD20, leading to depletion of CD20+ B cells through multiple immunological mechanisms. Combined, the regimen aims for synergistic anti-tumor activity in B-cell lymphoma by simultaneously targeting different B-cell antigens and mechanisms[1][3][4][5].
- Other names
- debio 1562m + rituximab
02
Targets
Beyond the preview
Go deeper on debio 1562 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on debio 1562 + rituximab.